ASP1012 in Locally Advanced or Metastatic Solid Tumors

What is the Purpose of this Study?

The goal of this study is to determine at what dose an experimental drug called ASP1012 is tolerated in people with locally advanced (spread to nearby areas) or metastatic (spread to distant parts) solid tumors that cannot be removed or have spread to other parts of the body. ASP1012 is a type of a virus that is designed to kill cancer cells and may help the patient’s own immune system to attack cancer cells. The drug has also been genetically changed so that it will preferentially grow in cancer cells rather than normal healthy cells. Participants will receive ASP1012 directly into their veins through an intravenous (IV) infusion.


Eligibility

  • * Participants in Parts 1 and 2 must have histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor(s).
  • * Dose Escalation (Part 1) - all previously treated participants with solid tumor types
  • * Dose Expansion (Part 2)
Show more

Where can I participate?

CS Cancer at The Angeles Clinic and Research Institute : Saba Mukarram

More about this Clinical Trial

What is the full name of this clinical trial?

1012-CL-0101: A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants with Locally Advanced or Metastatic Solid Tumors

Study Details
Disease Type/Condition

Colon, Melanoma, Other Female Genital, Rectum

Principal Investigator

Wentzel, Kristopher

Co-Investigators

Cathie T Chung, Inderjit Mehmi, Justin Moyers, Navid Hafez, Omid Hamid, Vi K. Chiu

Age Group

Adult

Phase

I

IRB Number

STUDY00003111

ClinicalTrials.gov ID

NCT06171178

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org
Study Detail
Disease Type/Condition

Colon, Melanoma, Other Female Genital, Rectum

Principal Investigator

Wentzel, Kristopher

Age Group

Adult

Phase

I

IRB Number

1012-CL-0101

ClinicalTrials.gov ID

NCT06171178

Key Eligibility
ClinicalTrials.gov

Contact
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org